SB 239063

SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD[1][2].

Product Specifications

CAS Number

[193551-21-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/SB-239063.html

Purity

99.49

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

COC1=NC=CC(C2=C(N=CN2[C@H]3CC[C@H](O)CC3)C4=CC=C(F)C=C4)=N1

Molecular Formula

C20H21FN4O2

Molecular Weight

368.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Underwood DC, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther. 2000 Apr;293 (1) :281-8.|[2]Matthew Huentelman, et al. Methods of treating memory loss and enhancing memory performance. US 20120245188 A1.